Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 4,465,000 | 2,447,000 | 7,071,000 | 5,082,000 | 2,982,000 |
| Depreciation Amortization | 1,645,000 | 823,000 | 3,538,000 | 2,655,000 | 1,808,000 |
| Accounts receivable | -939,000 | -751,000 | -383,000 | -194,000 | 200,000 |
| Other Working Capital | -1,969,000 | -1,305,000 | -771,000 | -665,000 | -342,000 |
| Other Operating Activity | 1,273,000 | 851,000 | 1,078,000 | 588,000 | 117,000 |
| Operating Cash Flow | $4,475,000 | $2,065,000 | $10,533,000 | $7,466,000 | $4,765,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 18,000 | -41,000 | N/A | -27,000 | 81,000 |
| PPE Investments | -700,000 | -321,000 | -1,885,000 | -1,271,000 | -810,000 |
| Net Acquisitions | 48,000 | N/A | -53,000 | -53,000 | 33,000 |
| Purchase Of Investment | N/A | N/A | -173,000 | N/A | N/A |
| Sale Of Investment | N/A | N/A | 77,000 | N/A | N/A |
| Other Investing Activity | 10,000 | 2,000 | 26,000 | 14,000 | 10,000 |
| Investing Cash Flow | $-624,000 | $-360,000 | $-2,008,000 | $-1,337,000 | $-686,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 13,000 | 8,000 | -204,000 | -7,000 | 20,000 |
| Debt Issued | 6,000 | N/A | 4,000 | 0 | 0 |
| Debt Repayment | -752,000 | -751,000 | -48,000 | -45,000 | -5,000 |
| Common Stock Issued | 69,000 | 59,000 | 255,000 | 173,000 | 103,000 |
| Common Stock Repurchased | -2,312,000 | -2,307,000 | -2,299,000 | -1,325,000 | -746,000 |
| Dividend Paid | -1,660,000 | -832,000 | -3,202,000 | -2,404,000 | -1,603,000 |
| Financing Cash Flow | $-4,636,000 | $-3,823,000 | $-5,494,000 | $-3,608,000 | $-2,231,000 |
| Exchange Rate Effect | -77,000 | -6,000 | -70,000 | -57,000 | -28,000 |
| Beginning Cash Position | 9,799,000 | 9,799,000 | 6,838,000 | 6,838,000 | 6,838,000 |
| End Cash Position | 8,937,000 | 7,675,000 | 9,799,000 | 9,302,000 | 8,658,000 |
| Net Cash Flow | $-862,000 | $-2,124,000 | $2,961,000 | $2,464,000 | $1,820,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 4,475,000 | 2,065,000 | 10,533,000 | 7,466,000 | 4,765,000 |
| Capital Expenditure | -700,000 | -321,000 | -1,885,000 | -1,271,000 | -810,000 |
| Free Cash Flow | 3,775,000 | 1,744,000 | 8,648,000 | 6,195,000 | 3,955,000 |